Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Enable Injections: Cincinnati-based Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable's body-worn enFuse® delivers large-volume therapeutics via subcutaneous administration, with the aim of improving convenience, potentially supporting improved safety outcomes, and advancing healthcare system economics. Approved in the United States in combination with a specific drug, more information.

## Sitemaps
[XML Sitemap](https://enableinjections.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi](https://enableinjections.com/enable-injections-announces-ce-certification-of-the-enfuse-on-body-delivery-system-for-use-with-aspaveli-distributed-by-sobi/): Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe
- [Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution.](https://enableinjections.com/aptar-digital-health-partners-with-enable-injections-for-enfuse-companion-digital-solution/): CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable’s preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help strengthen engagement support before, during and after administration. 
- [Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities](https://enableinjections.com/enable-injections-announces-30-million-investment-from-sanofi-to-accelerate-manufacturing-capabilities/): CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable’s manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth.
- [Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology](https://enableinjections.com/enable-injections-announces-regulatory-approval-in-saudi-arabia-for-the-empaveli-injector-based-on-enfuse-technology/): CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced that the EMPAVELI® Injector, based on enFuse technology, has received marketing authorization from the Saudi Food and Drug Authority (SFDA). The authorization for the injector and syringe transfer system is granted under the SFDA’s Medical Device Marketing Authorization (MDMA) framework, the regulatory clearance required for legal sale and distribution of medical devices in the Kingdom of Saudi Arabia.
- [Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System](https://enableinjections.com/incyte-and-enable-injections-announce-strategic-partnership-for-enfuse-on-body-delivery-system/): WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)--Oct. 27, 2025-- Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse® On-Body Delivery System.
- [Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK](https://enableinjections.com/enable-injections-announces-enfuse-system-regulatory-approval-in-brazil-and-mrha-medical-device-registration-in-the-uk/): CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® on-body drug delivery system, announced today that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA) approved the enFuse system for administration of medication subcutaneously.
- [Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025](https://enableinjections.com/survey-results-highlighting-missed-opportunities-in-subcutaneous-oncology-drug-development-at-aacr/): CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, announced today the presentation of a poster featuring new findings from a survey of drug development experts exploring the systemic underutilization of promising large-volume subcutaneous oncology therapies and misconceptions hindering their development at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, in Chicago.
- [Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology](https://enableinjections.com/enable-injections-announces-regulatory-ce-mark-approval-in-europe-for-enfuse-technology/): CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, today announced it has received its European Union Medical Device Regulation (EU MDR) CE Mark approval of the enFuse Syringe Transfer System. This approval allows Enable to deliver its innovative solutions throughout the EU.
- [An Award-Winning Year: A Look Back at 2024](https://enableinjections.com/an-award-winning-year-a-look-back-at-2024/): As the year draws to a close, it’s easy to forget some of the milestones from earlier in the year. Before we fully focus on the year ahead and beyond, here’s a look back at 2024:
- [Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories](https://enableinjections.com/enable-injections-announces-agreement-with-sobi-to-develop-and-distribute-aspaveli-in-combination-with-enfuse-in-sobi-territories/): CINCINNATI,  September 12, 2024  – Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, and Swedish Orphan Biovitrum AB (“Sobi”), a commercial-stage biotechnology company focusing on rare and debilitating diseases, today announced an international  development and distribution agreement for the enFuse® Injector, for the subcutaneous delivery of Aspaveli® (pegcetacoplan).
- [Enable Injections Names Matthew Huddleston as Chief Commercial Officer](https://enableinjections.com/enable-injections-names-matthew-huddleston-as-chief-commercial-officer/): CINCINNATI, May 22, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform today announced the appointment of Matthew Huddleston, previously Executive Vice President and Chief Technology Officer at Enable, to Chief Commercial Officer.
- [Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease](https://enableinjections.com/enable-injections-and-serina-therapeutics-announce-agreement-to-develop-ser-252-in-combination-with-enfuse-for-advanced-parkinsons-disease/): CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform and Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its POZ Platform™ to develop and improve efficacy and safety across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs), today announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s disease.
- [Enable Injections Expands Strategic Partnership with Roche](https://enableinjections.com/enable-injections-expands-strategic-partnership-with-roche/): CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery device technology, today announced the Company has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise and enFuse delivery technology to specific Roche development programs. Through this collaboration, Roche will obtain a worldwide, exclusive license to develop and commercialize combinations of the enFuse technology with specific Roche molecules. Enable will be responsible for clinical and commercial manufacturing and supply of the enFuse system.
- [Greg Etter Joins Enable Injections as VP, Engineering and Automation](https://enableinjections.com/greg-etter-joins-enable-injections-as-vp-engineering-and-automation/): We are pleased to announce Greg Etter has joined Enable Injections as the Vice President of Engineering and Automation. In this role, Greg will be responsible for leading the advancement of Enable’s equipment and automation projects as we scale up our commercial operations. With Enable’s investment in the new Center of Excellence for Manufacturing in Springdale, a significant portion of that expansion is the equipment, processes, and automation needed for our second high-volume production line. Greg will lead those efforts, building on the great work done by the manufacturing development teams to date.
- [Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters](https://enableinjections.com/enable-injections-announces-plans-to-expand-manufacturing-facilities-and-corporate-headquarters/): New state-of-the-art facility to be located in Springdale, Ohio
- [Enable Injections Appoints David Kroekel as Chief Operating Officer](https://enableinjections.com/enable-injections-appoints-david-kroekel-as-chief-operating-officer/): “David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development,” said Mike Hooven, Chairman and CEO of Enable Injections. “In the past year, Enable has poised itself for long-term commercial success and increasing product demand – with the U.S. FDA approval of the Company’s first enFuse combination product, and three high-value collaborations with both new and existing partners. David’s leadership at Enable has played a pivotal role in our Company’s success to date and we are excited to have him in this new position as COO as we continue driving innovation for enFuse and bringing this game-changing technology to our partners, HCPs, and most importantly – patients.” 
- [Beyond the Point: Navigating the Impact of Needles on Pain, Anxiety, and the Patient Experience](https://enableinjections.com/beyond-the-point-navigating-the-impact-of-needles-on-pain-anxiety-and-the-patient-experience/): From ONdrugDelivery January 2023:
- [Enable Injections Enhances Board with Addition of Vickie Capps](https://enableinjections.com/enable-injections-enhances-board-with-addition-of-vickie-capps/): New director, Vickie Capps, brings comprehensive financial expertise and leadership experience to Enable Injections, serving as head of the audit committee.
- [The Call for Freedom – A Patient’s Perspective on Today’s Drug Delivery Systems](https://enableinjections.com/the-call-for-freedom-a-patients-perspective-on-todays-drug-delivery-systems/): More than 133 million people in the United States live with a chronic disease2, which is defined as a “condition that lasts one year or more and requires ongoing medical attention or limits activities of daily living or both.”1 Pharmaceutical companies create medications to address health concerns, but treatment options can lack convenience and ease-of-use for patients. Many of these life-changing treatments must be delivered parenterally, or through intravenous (IV) or subcutaneous routes of administration, to bypass the digestive system, and be effective for the patient. But this type of delivery has challenges, often including poor ease-of-use, larger needles,  visible needles, and more. While patients often regain their health from these therapeutics, current delivery options take additional time and resources.  From long infusions in an IV chair in the clinic to cumbersome processes for patients to navigate on their own at home, these challenges often create burdens for patients.
- [Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval](https://enableinjections.com/enable-injections-receives-first-u-s-food-and-drug-administration-fda-approval/): The FDA has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of Apellis’ EMPAVELI® (pegcetacoplan)
- [A New Frontier: Self-Administration of Lyophilized, Large-Volume Subcutaneous Biologics](https://enableinjections.com/a-new-frontier-self-administration-of-lyophilized-large-volume-subcutaneous-biologics/): From ONdrugDelivery September 2023:
- [Introducing Enable Injections’ New Careers Site!](https://enableinjections.com/introducing-enable-injections-new-careers-site/): Visit our new careers site to learn more about our collaborative, innovative culture, employee benefits, and view current open positions. Stay up to date on the latest openings by joining our talent community or connect with us via email at careers@enableinjections.com.
- [Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections](https://enableinjections.com/viridian-therapeutics-announces-partnership-with-drug-delivery-innovator-enable-injections/): WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.
- [Sustainability Improvements in Drug Delivery with Allison Mack](https://enableinjections.com/sustainability-improvements-in-drug-delivery-with-allison-mack/): The carbon footprint of an IV infusion may be more than you think. Hear more from Allison Mack, Medical Education Lead at Enable Injections, about the waste comparison of a standard IV and the enFuse systems in our latest #EnableWearableDelivery executive video series!
- [Reduce Pharma Development Time: Large-Volume Subcutaneous Delivery with the enFuse](https://enableinjections.com/reduce-pharma-development-time-large-volume-subcutaneous-delivery-with-the-enfuse/): Subcutaneous (SC) drug development presents several challenges, and these challenges are amplified when trying to achieve a low-volume formulation. Intravenous (IV) administration has a bioavailability of 100%, but the bioavailability for SC monoclonal antibody drugs is 60%–80%. This means the dose is typically higher for SC delivery than for IV delivery to achieve therapeutic efficacy.
- [Dave Kroekel Promoted to Senior Vice President, Product Development & Operations](https://enableinjections.com/dave-kroekel-promoted-to-senior-vice-president-product-development-operations/): We are happy to announce Dave Kroekel’s promotion to Senior Vice President, Product Development & Operations, and newest member of the Executive Team. In Dave’s new role, he will continue to be responsible for Product Development and will now also have responsibility for Manufacturing, Supply Chain, and all Operations.
- [Sustainability Improvements in Drug Delivery: A Waste Comparison of IV vs. enFuse Large-Volume On-Body Delivery System](https://enableinjections.com/sustainability-improvements-in-drug-delivery-a-waste-comparison-of-iv-vs-enfuse-large-volume-on-body-delivery-system/): Our environment plays a huge factor in public health, and yet, the health sector is contributing significantly to climate change. Through building construction and operation, energy and resource consumption, and waste generation, health care operations are a significant source of carbon emissions around the world. Health care’s climate footprint is equivalent to 4-5% of global net emissions, which would be the fifth-largest emitter on the planet if it were its own country.2,3 As a result of the COVID-19 pandemic, the levels of medical waste has increased up to 10 times in healthcare facilities according to a WHO spokesperson.4  
- [The Real Role of Regulatory Affairs](https://enableinjections.com/the-real-role-of-regulatory-affairs/): Our next video in our Enable Wearable Delivery executive video series features Russ Pagano, Vice President of Regulatory Affairs & Quality. Tune in to learn more about how regulatory departments act as salespeople for a company!
- [Enable Injections Enhances Board with Addition of Nigel Sheail](https://enableinjections.com/enable-injections-enhances-board-with-addition-of-nigel-sheail/): New director, Nigel Sheail, adds global biopharma experience to Enable Injections, strengthening its mission to lead drug delivery innovation worldwide.
- [Enable Injections Commits to Cincinnati Growth with Increased Jobs](https://enableinjections.com/enable-injections-commits-to-cincinnati-growth-with-increased-jobs/): Enable Injections reinforces commitment to Cincinnati region with job and payroll expansion through state tax credit program and support from state organizations.
- [Thinking Clinically: Potential Benefits with the enFuse](https://enableinjections.com/thinking-clinically-potential-benefits-with-the-enfuse/): Transcript below:
- [Flexible Care: Enable Wearable Delivery](https://enableinjections.com/flexible-care-enable-wearable-delivery/): The following excerpt is originally published at ONdrugDelivery September 2022 issue, linked here.
- [enFuse Enables Flexibility for Pharma](https://enableinjections.com/enfuse-enables-flexibility-for-pharma/): Join our mission to redefine drug delivery with our new executive video series, Enable Wearable Delivery. The first video, "enFuse Enables Flexibility for Pharma" features Enable Injections' CEO Mike Hooven discussing the flexibility of the enFuse system.
- [Mehul Desai Joins Enable Injections as VP, Medical Affairs](https://enableinjections.com/mehul-desai-joins-enable-injections-as-vp-medical-affairs/): We are pleased to announce Mehul Desai, PharmD, MBA, has joined Enable Injections as Vice President of Medical / Clinical Affairs. Desai will lead Enable’s enFuse® medical and clinical programming to support publication, new partnerships, and regulatory approvals.
- [Enable Injections Enhances Board with Addition of John DeFord, Ph.D.](https://enableinjections.com/enable-injections-enhances-board-with-addition-of-john-deford-ph-d/): New director, John DeFord, Ph.D., adds global medical technology experience to Enable Injections, strengthening its mission to lead drug delivery innovation worldwide.
- [New Look, Same Mission – enFuse®](https://enableinjections.com/new-look-same-mission-enfuse/): Enable Injections is excited to introduce the new look for the enFuse® lid. The new enFuse lid design has an improved user interface with a streamlined dosing window and an enlarged area for branded product information.
- [Enable Injections Enhances Board with Addition of Three New Directors](https://enableinjections.com/enable-injections-enhances-board-with-addition-of-three-new-directors/): New directors add meaningful operating, investing and delivery systems experience to Enable Injections, strengthening its mission to lead drug delivery innovation worldwide.
- [Large-Volume Wearable Drug Delivery Technology Is Clinically Proven](https://enableinjections.com/large-volume-wearable-drug-delivery-technology-is-clinically-proven/): Opening Summary
- [Large-Volume Subcutaneous Delivery Is Feasible](https://enableinjections.com/large-volume-subcutaneous-delivery-is-feasible/): Current large-volume drug delivery methods generally require the patient and provider to be in the clinic. However, the desire to treat patients outside the clinic is growing, not only in the era of COVID-19, but also as treatment durations grow and disease is caught earlier. In our latest webinar, Pharma leaders, a KOL, and an innovator discussed technologies that can aid at-home patient-administered drug delivery – and how improving patient convenience can result in product differentiation and revenue growth. This post highlights the discussion around the first key point of the webinar: “Large-volume subcutaneous (SC) delivery is feasible”.
- [At-Home Drug Delivery of Large Molecule Medicines – The Future Is Now](https://enableinjections.com/at-home-drug-delivery-of-large-molecule-medicines-the-future-is-now/): Access the full webinar content here: At-Home Drug Delivery of Large Molecule Medicines.
- [Large-Volume Subcutaneous Delivery](https://enableinjections.com/large-volume-subcutaneous-delivery/): A 2019 study12 concludes the following pharmacokinetic and safety data comparing IV vs. SC administration:
- [Sanofi announces partnership with Enable Injections, Inc. on subcutaneous delivery for Sarclisa®](https://enableinjections.com/sanofi-announces-partnership-with-enable-injections-inc-on-subcutaneous-delivery-for-sarclisa/): In a press release today, Sanofi announces partnership with Enable Injections, Inc. on subcutaneous delivery for Sarclisa®.
- [Russell Pagano Joins Enable Injections as VP, Regulatory Affairs](https://enableinjections.com/russell-pagano-joins-enable-injections-as-vp-regulatory-affairs/): We are pleased to announce Russell Pagano, PhD, has joined Enable Injections as Vice President of Regulatory Affairs. Dr. Pagano will lead Enable’s enFuse® to its first regulatory submission and approval.
- [Reducing the Treatment Burden on Nurses](https://enableinjections.com/reducing-the-treatment-burden-on-nurses/): In September 2021, the American Nurses Association (ANA) published an article calling the “unsustainable nurse staffing shortage” in the United States a crisis.1 The current nursing shortage is a long-term problem amplified by the COVID pandemic and a continuing rise in healthcare demand--not a situation the ANA proposes will be easily solved. But there are steps that can alleviate the treatment burden on nurses, which could help.
- [Enable Injections Announces $215 Million Financing](https://enableinjections.com/enable-injections-announces-215-million-financing/): CINCINNATI, OH—January 27, 2022 /PRNewswire/ - Enable Injections, Inc. (“Enable”), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce $215 million in Series C financing. Magnetar Capital (“Magnetar”) led the financing along with new institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek Capital Partners, and other investors. Enable received significant continued support from existing investors including Cincinnati Children’s Hospital Medical Center, CincyTech, Cintrifuse, and Ohio Innovation Fund.
- [What Is Enable Injections’ Superpower?](https://enableinjections.com/what-is-enable-injections-superpower/): The Enable team is made up of passionate, entrepreneurial, and driven people who are working with a common goal of improving the lives of patients. In this brief video, we asked our team to share what they believe is Enable Injections’ superpower.
- [Getting Care to Patients – A New Paradigm](https://enableinjections.com/getting-care-to-patients-a-new-paradigm/): Key opinion leaders, Dr. John Fox and Dr. Len Lichtenfeld joined Enable Injections CEO, Mike Hooven, to discuss how Pharma can provide flexible care to patients, providers, and payers to create a better, more cost-effective, and differentiated infusion experience. A quick survey at the beginning of our webinar found that 56% of the audience says their company is currently investing in “bringing care to the patient”. In our webinar, Getting Care to Patients, we dive into why flexible care options are paving the future for healthcare.
- [Enable Manufacturing Excellence:](https://enableinjections.com/enable-manufacturing-excellence-state-of-the-art-modular-scalable-manufacturing/): Enable Injections Modular Scalable Manufacturing 1-minute video Showcase
- [Drug Delivery: What Do Patients and Providers Want?](https://enableinjections.com/drug-delivery-what-do-patients-and-providers-want/): In this article, originally published at OnDrugDelivery, Matthew Huddleston and Jennifer Estep discuss current drug delivery options and the value of convenient care.
- [Reimagining Patient Access to Treatment](https://enableinjections.com/reimagining-patient-access-to-treatment/): by Mike Hooven, CEO, Enable Injections - LinkedIn Published

## Pages
- [Approvals](https://enableinjections.com/approvals/): United States: The U.S. FDA approved the EMPAVELI® Injector combination product, based on enFuse® technology, for at-home self-administration with a specific drug.
- [Privacy Policy](https://enableinjections.com/privacy-policy/): Enable Injections (“Enable Injections,” “Company,” “we,” or “us”) is committed to protecting your privacy and ensuring transparency regarding how we collect, use, and safeguard personal information obtained through our website (the “Site”).This Privacy Policy explains our practices and describes your rights under applicable laws, including the California Consumer Privacy Act (CCPA).
- [Newsroom](https://enableinjections.com/newsroom/): New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
- [Certifications](https://enableinjections.com/certifications/): FM 635537 Current ISO Certificate
- [Commercial Products](https://enableinjections.com/commercial-products/): To learn more, visit  Empaveli.com or Apellis.com
- [Careers](https://enableinjections.com/careers/): Careers
- [Large-Volume Subcutaneous Delivery](https://enableinjections.com/large-volume-subcutaneous-delivery/): Figure 4. enFuse Large-Volume Subcutaneous Delivery Technology - Simplified
- [Enable Injections Purchase Order Terms & Conditions](https://enableinjections.com/poterms/): 1.4. “Order” means a purchase order issued by Enable Injections to Vendor, and includes these Conditions which are incorporated by reference.
- [Hear from our team](https://enableinjections.com/blog/)
- [Contact Us](https://enableinjections.com/contact-us/): Enable Injections is a healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse.
- [About](https://enableinjections.com/about/): Founded in 2010, Enable Injections is a healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse. 
- [Technology](https://enableinjections.com/technology/): The enFuse wearable platform is designed to deliver large volumes of medications subcutaneously, in which patients receive their needed treatment in a simple injection under the skin, instead of intravenously.
- [Home Page](https://enableinjections.com/): Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi

## News
- [Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector](https://enableinjections.com/news/press-release-sanofis-subcutaneous-sarclisa-escena-approved-in-the-us-as-first-anticancer-treatment-administered-via-on-body-injector/)
- [Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector](https://enableinjections.com/news/sanofis-sarclisa-subcutaneous-approved-in-the-eu-as-the-first-anticancer-treatment-administered-via-an-on-body-injector/)
- [Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi](https://enableinjections.com/news/enable-injections-announces-ce-certification-of-the-enfuse-on-body-delivery-system-for-use-with-aspaveli-distributed-by-sobi/)
- [Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma](https://enableinjections.com/news/sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma/)
- [Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution](https://enableinjections.com/news/aptar-digital-health-partners-with-enable-injections-for-enfuse-companion-digital-solution/)
- [Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities](https://enableinjections.com/news/enable-injections-announces-30-million-investment-from-sanofi-to-accelerate-manufacturing-capabilities/)
- [Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology](https://enableinjections.com/news/enable-injections-announces-regulatory-approval-in-saudi-arabia-for-the-empaveli-injector-based-on-enfuse-technology/)
- [Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System](https://enableinjections.com/news/incyte-and-enable-injections-announce-strategic-partnership-for-enfuse-on-body-delivery-system/)
- [Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK](https://enableinjections.com/news/enable-injections-announces-enfuse-system-regulatory-approval-in-brazil-and-mrha-medical-device-registration-in-the-uk/)
- [ASCO: new Sarclisa data support subcutaneous administration with on-body injector](https://enableinjections.com/news/asco-new-sarclisa-data-support-subcutaneous-administration-with-on-body-injector/)
- [Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025](https://enableinjections.com/news/enable-injections-presents-survey-results-highlighting-missed-opportunities-in-subcutaneous-oncology-drug-development-at-aacr-2025/)
- [Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology](https://enableinjections.com/news/enable-injections-announces-regulatory-ce-mark-approval-in-europe-for-enfuse-technology/)
- [New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma](https://enableinjections.com/news/new-sarclisa-subcutaneous-formulation-met-co-primary-endpoints-in-the-iraklia-phase-3-study-in-multiple-myeloma/)
- [Enable Injections Expands Strategic Partnership with Roche](https://enableinjections.com/news/enable-injections-expands-strategic-partnership-with-roche/)
- [Enable Injections Announces Agreement with Sobi to Develop and Distribute Aspaveli in Combination with enFuse in Sobi Territories](https://enableinjections.com/news/enable-injections-announces-agreement-with-sobi-to-develop-and-distribute-aspaveli-in-combination-with-enfuse-in-sobi-territories/)
- [Enable Injections Names Matthew Huddleston as Chief Commercial Officer](https://enableinjections.com/news/enable-injections-names-matthew-huddleston-as-chief-commercial-officer/)
- [Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse for Advanced Parkinson’s Disease](https://enableinjections.com/news/enable-injections-and-serina-therapeutics-announce-agreement-to-develop-ser-252-in-combination-with-enfuse-for-advanced-parkinsons-disease/)
- [Enable Injections and Flex Partner for Production of Wearable High Volume Injectors](https://enableinjections.com/news/enable-injections-and-flex-partner-for-production-of-wearable-high-volume-injectors/)
- [CincyTech predicts 600 new jobs with $30M fund](https://enableinjections.com/news/cincytech-predicts-600-new-jobs-with-30m-fund/)
- [Enable Injections Completes Cincinnati Manufacturing Facility for On-Body Delivery Systems](https://enableinjections.com/news/enable-injections-completes-cincinnati-manufacturing-facility-for-on-body-delivery-systems/)
- [Enable Injections Closes $30M Series A Financing Led by ORI Healthcare](https://enableinjections.com/news/enable-injections-closes-30m-series-a-financing-led-by-ori-healthcare/)
- [CincyTech 2016: Here We Grow](https://enableinjections.com/news/cincytech-2016-here-we-grow/)
- [2017 Innovation & Technology Award winner: Enable Injections](https://enableinjections.com/news/2017-innovation-technology-award-winner-enable-injections/)
- [Enable Injections Introduces First Multi-Vial/Multi-Syringe Biologics Delivery System For Several Pharma Partners at BIO 2017](https://enableinjections.com/news/enable-injections-introduces-first-multi-vial-multi-syringe-biologics-delivery-system-for-several-pharma-partners-at-bio-2017/)
- [Enable Injections Achieves ISO 13485:2016 Certification to Meet Mounting Demand for Drug-Delivery Device Combination Products](https://enableinjections.com/news/enable-injections-achieves-iso-134852016-certification-to-meet-mounting-demand-for-drug-delivery-device-combination-products/)
- [Enable Injections Names Jeannie Joughin, Ph.D. Executive Vice President and Chief Commercial Officer](https://enableinjections.com/news/enable-injections-names-jeannie-joughin-ph-d-executive-vice-president-and-chief-commercial-officer/)
- [Enable Injections Granted U.S. Utility Patent in Expanding IP Portfolio](https://enableinjections.com/news/enable-injections-granted-u-s-utility-patent-in-expanding-ip-portfolio/)
- [Enable Injections’ First Closing of Series B Round to Include a New Investor: Financing to Accelerate Commercial Manufacturing](https://enableinjections.com/news/enable-injections-first-closing-of-series-b-round-to-include-a-new-investor-financing-to-accelerate-commercial-manufacturing/)
- [Enable Injections Enters into Strategic Partnerships with UCB and Apellis Pharmaceuticals](https://enableinjections.com/news/enable-injections-enters-into-strategic-partnerships-with-ucb-and-apellis-pharmaceuticals/)
- [Enable Injections inks development deals with pharma firms](https://enableinjections.com/news/enable-injections-inks-development-deals-with-pharma-firms/)
- [PM360 Presents the 2018 Innovators](https://enableinjections.com/news/pm360-presents-the-2018-innovators/)
- [Evendale startup wants to change how you take medicine; IPO up next for Enable Injections](https://enableinjections.com/news/evendale-startup-wants-to-change-how-you-take-medicine-ipo-up-next-for-enable-injections/)
- [Highlighting Partner Success, brief video, SAP.com](https://enableinjections.com/news/highlighting-partner-success-brief-video-sap-com/)
- [Enable Injections Enters into Strategic Partnership with Sanofi](https://enableinjections.com/news/enable-injections-enters-into-strategic-partnership-with-sanofi/)
- [Cincinnati Firm Inks Land Deal, Plans Huge Expansion](https://enableinjections.com/news/cincinnati-firm-inks-land-deal-plans-huge-expansion/)
- [Enable Injections Enters into Strategic Partnership with Genentech, a Member of the Roche Group](https://enableinjections.com/news/enable-injections-enters-into-strategic-partnership-with-genentech-a-member-of-the-roche-group/)
- [Innovate Live – Software Solutions Helping to Bring the enFuse® to Market, NYC](https://enableinjections.com/news/innovate-live-software-solutions-helping-to-bring-the-enfuse-to-market-nyc/)
- [Enable Injections Turns to SAP and Partner Dickinson + Associates to Prepare for Growth (brief video)](https://enableinjections.com/news/enable-injections-turns-to-sap-and-partner-dickinson-associates-to-prepare-for-growth-brief-video/)
- [Enable Injections Looks to Reinvent Medical Injections, Scale](https://enableinjections.com/news/enable-injections-looks-to-reinvent-medical-injections-scale/)
- [8 Cincinnati biotech companies with big steps to watch in 2020](https://enableinjections.com/news/8-cincinnati-biotech-companies-with-big-steps-to-watch-in-2020/)
- [Enable Injections Announces $25 Million Credit Facility Closed with Oxford Finance](https://enableinjections.com/news/enable-injections-announces-25-million-credit-facility-closed-with-oxford-finance/)
- [Success Connect – SAP S/4Hana, Success Factors Panel video](https://enableinjections.com/news/success-connect-sap-s-4hana-success-factors-panel-video/)
- [Business Insider – Enable Injections, Drug Delivery & Ohio Roots](https://enableinjections.com/news/business-insider-enable-injections-drug-delivery-ohio-roots/)
- [Enable Injections Announces $215 Million Financing](https://enableinjections.com/news/enable-injections-announces-215-million-financing/)
- [Sanofi announces €300million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma](https://enableinjections.com/news/sanofi-announces-e300million-collaboration-with-blackstone-life-sciences-to-advance-an-innovative-treatment-for-multiple-myeloma/)
- [Enable Injections Enhances Board with Addition of Three New Directors](https://enableinjections.com/news/enable-injections-enhances-board-with-addition-of-three-new-directors/)
- [Enable Injections Enhances Board with Addition of John DeFord, Ph.D.](https://enableinjections.com/news/enable-injections-enhances-board-with-addition-of-john-deford-ph-d/)
- [Enable Injections Commits to Cincinnati Growth with Increased Jobs](https://enableinjections.com/news/enable-injections-commits-to-cincinnati-growth-with-increased-jobs/)
- [Enable Injections Enhances Board with Addition of Nigel Sheail](https://enableinjections.com/news/enable-injections-enhances-board-with-addition-of-nigel-sheail/)
- [Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections](https://enableinjections.com/news/viridian-therapeutics-announces-partnership-with-drug-delivery-innovator-enable-injections/)